Genmab's EPCORE DLBCL-1 Phase 3 trial posts results after primary completion in October 2026
Results for the Phase 3 trial comparing epcoritamab to chemotherapy in relapsed/refractory DLBCL were posted as of November 3, 2026.
A single update on an ongoing Phase 3 program for epcoritamab in diffuse large B-cell lymphoma marks the week's activity.
- Epcoritamab (EPKINLY, GEN3013), Phase 3, relapsed/refractory DLBCL: results were first posted on 2026-11-03 for the trial known as "EPCORE DLBCL-1," sponsored by Genmab with AbbVie as collaborator. The study enrolled 483 participants1 and reached actual primary completion on 2025-10-131, comparing epcoritamab against investigator's choice chemotherapy (R-GemOx or bendamustine plus rituximab) in participants randomly assigned to receive either epcoritamab or a pre-specified investigator's choice standard of care chemotherapy1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.